DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Glofitamab + Polatuzumab Show Durable Responses In R/R DLBCL With Manageable Safety Profile Sep 11, 2023
DLBCL (Diffuse Large B Cell Lymphoma) Results for Anti-CD19 Allogeneic Car T in R/R LBCL Sep 08, 2023
DLBCL (Diffuse Large B Cell Lymphoma) Bispecific Anti-CD20/19 CAR-T Zamtocabtagene Autoleucel Show Promising Results In R/R DLBCL Sep 06, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Liso-cel Proves Safe And Effective For R/R LBCL Patients Aug 30, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Subcutaneous Epcoritamab Achieved Complete Remissions In R/R LBCL Aug 24, 2023
Lymphoma,MCL (Mantle Cell Lymphoma) Impact of Rituximab Maintenance on Young Pts With MCL Aug 21, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma,MZL (Marginal Zone Lymphoma) AUTO4 Shows Tolerance in Patients With TRBC1-Positive PTCL Aug 21, 2023
Lymphoma,MZL (Marginal Zone Lymphoma) Rituximab Plus Ibrutinib Show Efficacy and Safety in Untreated MZL Aug 18, 2023